More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$10.69B
P/E ratio
25.6
Dividend yield
0.1559%
Expense ratio
0.44%
Beta
0.720408
Previous close
$207.98
Today's open
$207.47
Day's range
$204.57 - $208.10
52 week range
$159.68 - $222.29
show more
Headquarters
US
Exchange
NASDAQ Global Market
Issue type
Exchange-Traded Fund
Industries
Health
8.94%
AMGN
Amgen Inc
8.31%
7.87%
6.24%
MRNA
Moderna Inc
5.49%
NTRA
Natera Inc
3.78%
ARGX:AS
Argenx SE ADR
3.36%
BIIB
Biogen Inc
2.52%
2.5%
ILMN
Illumina Inc
2.41%
Which Healthcare ETF Is the Better Buy: State Street's Pharma Fund XPH or iShares' Biotech Fund IBB?
State Street SPDR S&P Pharmaceuticals ETF has a lower expense ratio and a higher trailing dividend yield. iShares Biotechnology ETF is significantly larger by assets under management.
The Motley Fool • Nov 15, 2026

Which Healthcare ETF Is the Better Buy: VanEck's Pharma Fund PPH or iShares' Biotech Fund IBB?
VanEck Pharmaceutical ETF offers a lower expense ratio and a higher dividend yield than iShares Biotechnology ETF. iShares Biotechnology ETF provides broader exposure with over 200 holdings, while VanEck Pharmaceutical ETF concentrates on 26 pharmaceutical leaders.
The Motley Fool • Nov 15, 2026

Two Ways to Play Biotech: FBT's Return Edge vs. IBB's Cost Advantage
First Trust NYSE Arca Biotechnology Index Fund maintains a more concentrated portfolio of 30 holdings compared to the 243 positions found in iShares Biotechnology ETF. iShares Biotechnology ETF carries a lower expense ratio of 0.44% whereas First Trust NYSE Arca Biotechnology Index Fund charges 0.55%.
The Motley Fool • Nov 14, 2026

Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors
The iShares U.S. Pharmaceuticals ETF offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides exposure to a broader group of 243 companies, while the iShares U.S. Pharmaceuticals ETF is concentrated in only 53 holdings.
The Motley Fool • Nov 7, 2026

Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
U.S. midterm results signal a "Blue Wave," with Democrats controlling both House and Senate, likely impacting healthcare policy and funding. Health insurers like UnitedHealth and CVS Health typically rebound after policy shocks; Oscar Health stands out for ACA-driven growth and innovation.
Seeking Alpha • Nov 5, 2026

How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks
Many of the hot new drug candidates in the U.S. were developed Chinese companies.
Barrons • Nov 3, 2026

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
Zacks Investment Research • Nov 2, 2026

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%
A single health care ETF launched two decades ago at rock-bottom cost has quietly compounded into a sum that surprises most investors, but whether its three closest rivals can match it depends entirely on what kind of risk you are
24/7 Wall Street • Oct 31, 2026

Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.
24/7 Wall Street • Oct 30, 2026

Should You Invest in the iShares Biotechnology ETF (IBB)?
Launched on February 5, 2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Zacks Investment Research • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell iShares NASDAQ Biotechnology ETF commission-free¹. Build wealth for the long term using automated trading and transfers.